ArticleIJU case reports2026
Radiation-Associated Enteric-Type Urethral Adenocarcinoma 20 Years After Prostate Brachytherapy: A Case Treated With Neoadjuvant Gemcitabine-Cisplatin and Robot-Assisted Radical Cystectomy.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Brachytherapy is a widely accepted treatment for prostate cancer, in which subsequent radiation-associated enteric-type urethral adenocarcinoma is extremely rare. Case Presentation: An 83-year-old man with a history of cholecystitis, appendicitis, and hyperlipidemia who had undergone brachytherapy 20 years earlier presented with dysuria. Transurethral resection of the prostate revealed enteric-type urethral adenocarcinoma. Imaging showed a space-occupying lesion extending from the prostatic to the membranous urethra without distant metastasis. The patient received three cycles of gemcitabine and cisplatin as neoadjuvant chemotherapy, followed by robot-assisted radical cystectomy after confirmation of tumor shrinkage. At 18 months postoperatively, he remained alive with no evidence of recurrence. Conclusion: This case illustrates a rare secondary enteric-type urethral adenocarcinoma after brachytherapy and highlights a potential therapeutic strategy for its management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.